As we wrap up this year and look ahead to 2025, we are more driven than ever to deliver on our purpose: to be the biotech leader that translates the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The BioMarin 8 – our core Operating Principles – provide the framework for how we work together every day to fulfill that purpose.
View Post
Meet DMD. This gene provides instructions for making dystrophin, a protein that plays an essential role in strengthening and protecting muscle fibers. Changes in the DMD gene can result in a degenerative neuromuscular condition called Duchenne muscular dystrophy. We’re researching the potential to improve outcomes for people living with Duchenne muscular dystrophy by developing a medicine that may improve the levels of dystrophin in the muscle cells of those with the condition.
View Post
RARE Scholars award recipient Brian DuVal is pursuing his Master of Public Health at Vanderbilt University in Tennessee. He aspires to become a leader in the hemophilia community and use his influence to improve the lives of others living with rare conditions.
View Post
We’re looking forward to the #TruePKU meeting next year, which will be the first opportunity for U.S. regulators to hear directly from the #PKU community in a public forum in more than a decade. We’re proud to support the National PKU Alliance's efforts to integrate the perspectives of people living with PKU into the process of developing new therapeutic options and are grateful that the #FDA has made this opportunity possible by granting this EL-PFDD.
View Post